Skip to main content

TELUS donates $500,000 to support global-leading research team develop antiviral treatments for COVID-19

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, March 27, 2020 (GLOBE NEWSWIRE) — TELUS today announced a $500,000 donation to the Vancouver Prostate Centre (VPC), Vancouver General Hospital (VGH) and University of British Columbia (UBC) Hospital Foundation to assist in the search for therapeutic antiviral treatments for COVID-19. Led by Professor Art Cherkasov, VPC and UBC scientists have joined forces with experts around the world including collaborations with Cambridge in the UK, Memorial Sloan-Kettering in New York, University of North Carolina Pharma Science, and Enamine, the biggest small molecule supplier in the world, in the Ukraine. This Vancouver-led team brings together some of the best talent in the world in medicinal chemistry and virology.
‘‘We are encouraged by the incredible expertise of the researchers that make up this global consortium as they rapidly search for COVID-19 treatments. As a world leader in social capitalism, it is our hope that this inaugural TELUS donation to a leading institution at the forefront of healthcare research will positively impact the lives of Canadians and of others internationally,’’ said Darren Entwistle, President and CEO. ‘‘As TELUS actively helps customers and citizens to support better health outcomes during this unprecedented time, we are also providing funding to bolster public healthcare capacity, enabling virtual healthcare to reduce risk of exposure, repurposing our mobile health clinics to support COVID-19 testing, and sourcing medical supplies and technology for healthcare workers.”“TELUS’ generous support will fast track the ability to screen this shortlist and provide BC and global colleagues an enormous push towards developing an antiviral small molecule therapeutic for COVID-19 as quickly as possible,” said Dr. Larry Goldenberg, Director of Development at VPC and UBC, Professor of Urologic Sciences, and recipient of the Order of British Columbia, and Member of the Order of Canada. “Funding will help to expand our resources including scientists, research assistants, reagents, equipment and operational costs. We encourage more organizations to help fund this vital research.”Research teams around the world are seeking development of vaccines, antibodies or protease inhibitors. The VPC’s cutting-edge platforms, highly developed for precision cancer drug discovery, have been rapidly repurposed to address today’s health crisis by shaving significant time off the process of finding a cure for COVID-19. VPC, with its expertise, facilities and capabilities in cutting edge Artificial Intelligence (AI), is poised to make a remarkable difference in the global race for an anti-protease treatment for COVID-19. Its unique AI system allowed for accelerated computerized screening of 1.3 billion chemicals to create a shortlist of 100 potential therapeutic compounds in one week, as opposed to conventional methods that could take up to three years.Organizations interested in funding this critical research can learn more by visiting https://vghfoundation.ca/COVID-19-response/. To learn more about the research visit www.prostatecentre.com.For the latest information about TELUS’ support during the crisis, visit telus.com/covid19.About TELUS
TELUS (TSX: T, NYSE: TU) is a dynamic, world-leading communications and information technology company with $14.7 billion in annual revenue and 15.2 million customer connections spanning wireless, data, IP, voice, television, entertainment, video and security. We leverage our global-leading technology to enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. TELUS Health is Canada’s largest healthcare IT provider, and TELUS International delivers the most innovative business process solutions to some of the world’s most established brands.Driven by our passionate social purpose to connect all Canadians for good, our deeply meaningful and enduring philosophy to give where we live has inspired our team members and retirees to contribute more than $700 million and 1.3 million days of service since 2000. This unprecedented generosity and unparalleled volunteerism have made TELUS the most giving company in the world.For more information about TELUS, please visit telus.com, follow us @TELUSNews on Twitter and @Darren_Entwistle on Instagram.For more information, please contact:Brandi Rees
TELUS Public Relations
brandi.rees@telus.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.